Cardiolyse Oy

Cardiolyseis a deep tech startup, with R&D team comprising of 9 PhDs in Cardiology, Cybernetics, Neural Networks and Data Science in Kiev, Ukraine and the company HQ in Helsinki, Finland (where it is resident at the elite GE Healthcare Innovation Village). It was also a in a last cohort Digital Health Startupbootcamp member in Berlin (top dozen of European health startups chosen), working with Europe's top pharma corporations. The company has been founded by Prof. Illya Chaikovsky, MD, PhD multiple, who spend 25 years in cardiology (practising) and is a lead scientist at the Institute of Cybernetics, a part of the Ukrainian Academy of Science. The Institute was involved in the Soviet space programme research, particularly exploring ways of effective algorithmic based prediction of heart disease, as it poses a heightened risk for astronauts. Cardiolyse has developed a cloud based ECG/PPG data processing platform (device agnostic - able to get data from any device), which provides output based on their ground-breaking ECG & HRV Heart and Emotional Score system (patent pending). This scoring system enables complex heart health management (self-managed and in cooperation with healthcare providers). The core invention, unique on a world scale, are algorithms that are able to predict cardiac-related disease accurately up to 3 months in advance of current symptoms and allow tracking heart reactions to everyday activities, enabling recommendations for individual lifestyle change(s). It defines over 400 parameters, all essential to understanding heart health. Each heart parameter is placed on a scale from a normal to pathological, making any electrocardiogram informative and conclusive; they are then grouped into several blocks vital for daily health management (giving a ‘Heart Wellbeing Score’). The platform uses three classes of algorithms that provide respective conclusions: Preventive - generalized conclusions regarding the person’s functional state, stamina, heart muscle state, psychological emotional state, heart biological age, stress levels, etc. Diagnostic - formulated in specific disease terms for a medical professional, and covering such conditions as ischemia, arrhythmias, hypertrophy of the heart chambers, conduction defects. Prognostic - a forecast of the probable course and outcome of heart disease, including the probability of patient recovery The proprietary parameters are very sensitive to subtitle changes of physiological state and help us to see how lifestyle and day-by-day routine (food, cardio drugs, rest, stress, workouts, etc) impact the heart health. Those parameters consist of: trends of stamina level, myocardium state, stress and psycho-emotional indexes, degree of heart rhythm disturbances show the interconnection between lifestyle, heart and emotional conditions and help to prevent heart disorders.Cardiolyse supports behavioural change (driving prevention of CVD’s), by providing easy to understand, precise and individualized information about user’s physiological state and heart health and preventing the readmission for chronic patients, keeping more people out of the hospitals.The technology enables medical grade population heart health monitoring, without the need of medical professionals or hospitals/clinic. Cardiolyse is a part of University of Oxford Innovation network, their technology has been validated at the Oxford University Nuffield Department of Population Studies for the past three years. Endorsement of the technology by the University of Oxford gave them a very high credibility, particularly in Asia, Middle East and Africa.It is already commercially deployed with partner companies in India, providing rural health population ECG screening; as a member of Oxford University Open Innovation network, they signed an agreement to enter China and as a winner of Sanofi challenge at ViVa Tech conference this year in Paris, they are working on entering Africa with Sanofi.Furthermore, based on their core technology, they have developed a unique (on a global scale) Fatigue Risk Management Platform, which enables insurance companies to lower their risk exposure to accidents caused by fatigue.Cardiolyse offers the first real-time fatigue risk management solution that enables tracking fatigue-related risks.It found It found a very interesting use of its technology for the insurance industry, which provides essential (and often mandatory) liability cover for critical services (eg healthcare), where the risk exposure caused by human error due to fatigue is very high, triggering large insurance claims. Cardiolyse was chosen by one of the biggest insurance companies to develop a Fatigue Risk Management Platform which would allow for active constant monitoring of fatigue levels for workers at risk of developing it, allowing for intervention when it becomes dangerous. The main aim is to lower their risk exposure (by helping to reduce the number of accidents) and for them in turn to reduce insurance premiums to their corporate customers who implement our Platform. This is industry first, breakthrough application of Machine Learning algorithms and digital health wearable devices to managing Fatigue Risk. For health insurance, it offers a digital integrated solution to prevent cardiovascular complications in diabetes through affordable comprehensive monitoring offers the best market potential, specifically partnering with pharma and health insurance companies as distribution channels Heart disease is common in people with diabetes. Data from the National Heart Association from 2012 shows 65% of people with diabetes will die from some sort of heart disease or stroke. In general, the risk of heart disease death and stroke are twice as high in people with diabetes. While all people with diabetes have an increased chance of developing heart disease, the condition is more common in those with type 2 diabetes. In fact, heart disease is the number one cause of death among people with type 2 diabetes.